Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
- Conditions
- HIVAcute HIV Infection
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 40
- Registration Number
- NCT02384395
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Duke University Health System, Durham, North Carolina, United States
Test Albuvirtide in Experienced Patients
- Conditions
- HIV InfectionsAIDS
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 418
- Registration Number
- NCT02369965
- Locations
- 🇨🇳
The Third People'S Hospital Of Shenzhen, Shenzhen, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Beijing Youan Hospital, Capital medical university, Beijing, Beijing, China
Early Infant HIV Treatment in Botswana
- Conditions
- HIVPediatric AIDS
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Harvard School of Public Health (HSPH)
- Target Recruit Count
- 67
- Registration Number
- NCT02369406
- Locations
- 🇧🇼
Botswana Harvard HIV/AIDS Institute Partnership, Gaborone, Botswana
Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2015-01-13
- Target Recruit Count
- 500
- Registration Number
- NCT02337127
- Locations
- 🇨🇳
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, NRW, Taiwan
The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children
- Conditions
- the Safety of Anti-viral Drugs Used in Late Pregnancy
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02301650
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
- Conditions
- Pediatric Immuno-Tolerant Chronic Hepatitis B
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT02263079
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇮🇹Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive, Bologna, Emilia-Romagna, Italy
🇩🇪Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II, Essen, Germany
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Babafemi Taiwo
- Target Recruit Count
- 89
- Registration Number
- NCT02263326
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02249130
Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Lamivudine+Oxymatrine Capsules
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Southeast University, China
- Target Recruit Count
- 192
- Registration Number
- NCT02202473
- Locations
- 🇨🇳
the second hospital of Nanjing, Nanjing, Jiangsu, China
Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2648
- Registration Number
- NCT02181933
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.